CHRS, US19249H1032

Coherus Oncology stock heads toward its October 7 CVR distribution

Published on 10/04/2026 at 19:13 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Coherus Oncology stock was last at USD 1.16 on October 2, while the company prepares a CVR distribution for October 7. Q2 revenue reached USD 14.31 million.

CHRS, US19249H1032, Illustration mit AI erstellt.

Coherus Oncology (ISIN US19249H1032) was last at USD 1.16 on Nasdaq on October 2, 2026, while its market capitalization stood at USD 179.2 million. The company is preparing a contingent value rights distribution for October 7 after launching a sale process for its legacy biosimilar assets.

CVR distribution follows asset sale process

According to Coherus Oncology in its September 23, 2026 release, the company retained Oppenheimer to market patents, royalties, cell lines and related materials from its former biosimilars business. The CVRs will go to shareholders of record on September 30, 2026, with distribution scheduled for October 7, 2026.

The rights are tied to net cash or other consideration that Coherus actually receives from a sale or licensing transaction. The release also states that holders could receive little or no payment if a transaction is not completed or produces less favorable terms, making the eventual proceeds a central uncertainty for the security.

Revenue expands while losses remain

For Q2 2026, Coherus reported revenue of USD 14.31 million and a GAAP net loss of USD 20.63 million, compared with USD 10.25 million of revenue and a USD 41.34 million loss in the year-earlier quarter, according to Markets Insider. Revenue therefore increased by USD 4.06 million, while the reported loss narrowed by USD 20.71 million.

Coherus ended Q2 with USD 82.92 million in cash and generated negative operating cash flow of USD 62.09 million, according to the latest quarterly financial data for the period ended June 30, 2026. The figures leave the company balancing commercial growth in LOQTORZI against continued cash use and the possibility of further financing.

Analyst target remains far above Nasdaq price

Markets Insider reported on September 21, 2026, that H.C. Wainwright reiterated a Buy rating with a USD 7.00 price target, while the published consensus was Strong Buy with an average target of USD 7.75. The consensus target lies 568.1 percent above the USD 1.16 Nasdaq price, a wide gap that reflects both expected oncology growth and the risks surrounding execution, cash needs and the legacy-asset process.

CHRS stays near its yearly low

CHRS was last at USD 1.16 on Nasdaq at 4:00 p.m. ET on October 2, 2026. Its 52-week range was USD 1.09 to USD 2.62, and trading volume reached 1,183,174 shares on that session.